Medigen Biotechnology (3176) reported revenue of NT$151.5 million for Oct 2026, +6.6% year on year and -40.6% from the previous month. Revenue for Jan–Oct 2026 was NT$1.38 billion (-1.4% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 55 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$151.5 million | +6.6% | -40.6% |
| Sep 2026 | NT$255.2 million | +49.6% | -22.5% |
| Aug 2026 | NT$329.2 million | +197.4% | +241.4% |
| Jul 2026 | NT$96.4 million | -16.4% | +1.7% |
| Jun 2026 | NT$94.8 million | -30.0% | -0.7% |
| May 2026 | NT$95.5 million | -19.8% | +1.2% |
| Apr 2026 | NT$94.4 million | -10.3% | -6.1% |
| Mar 2026 | NT$100.5 million | -67.9% | +48.4% |
| Feb 2026 | NT$67.7 million | -24.0% | -27.4% |
| Jan 2026 | NT$93.3 million | -4.0% | -1.3% |
| Dec 2025 | NT$94.5 million | -11.1% | +5.0% |
| Nov 2025 | NT$90 million | -17.2% | -36.7% |
| Oct 2025 | NT$142.1 million | +22.9% | -16.7% |
| Sep 2025 | NT$170.6 million | -14.4% | +54.1% |
| Aug 2025 | NT$110.7 million | -2.8% | -4.1% |
| Jul 2025 | NT$115.4 million | -6.6% | -14.9% |
| Jun 2025 | NT$135.5 million | +21.8% | +13.8% |
| May 2025 | NT$119.1 million | -16.2% | +13.2% |
| Apr 2025 | NT$105.2 million | +4.4% | -66.4% |
| Mar 2025 | NT$313 million | +203.0% | +251.3% |
| Feb 2025 | NT$89.1 million | +27.9% | -8.4% |
| Jan 2025 | NT$97.3 million | +24.2% | -8.5% |
| Dec 2024 | NT$106.3 million | +21.7% | -2.3% |
| Nov 2024 | NT$108.7 million | -14.7% | -6.0% |
| Oct 2024 | NT$115.7 million | -26.0% | -41.9% |
Jan–Oct 2026 cumulative: NT$1.38 billion (-1.4% YoY)
Other Biotech & Medical companies
Compare with peers: Medigen Biotechnology vs PEC / Medigen Biotechnology vs Lotus Pharm / Medigen Biotechnology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16